PTCT Q3 2024 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$197M+0.1% YoY

Gross Profit

$186M94.5% margin

Operating Income

-$55M-27.7% margin

Net Income

-$107M-54.2% margin

EPS (Diluted)

$-1.39

QoQ Revenue Growth

+5.4%

Cash Flow

Operating Cash Flow

-$77M

Free Cash Flow

-$88M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.9B

Stockholders' Equity

-$1.1B

Cash & Equivalents

$526M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$197M	$197M	+0.1%
Gross Profit	$186M	$187M	-0.6%
Operating Income	-$55M	-$118M	+53.9%
Net Income	-$107M	-$133M	+19.8%

Revenue Segments

Product

$135M69%

Royalty

$61M31%

Manufacturing

$800,0000%